SOD1 and amyotrophic lateral sclerosis: Based on the results from randomized controlled trials conducted in both the USA and Europe [15, 16], on 25 April 2023, tofersen received approval from the US Food and Drug Administration for treating ALS in adults carrying the SOD1 mutation.